CVRx to Present at the Canaccord Genuity 41st Annual Growth Conference

Rhea-AI Summary

CVRx announced its participation in the Canaccord Genuity 41st Annual Growth Conference scheduled for August 12, 2021 at 11:00 am ET. The management team will present via a live audio webcast accessible on the company's investor relations webpage. The presentation will also be archived for 90 days. CVRx focuses on minimally invasive solutions for cardiovascular diseases, notably the Barostim, which is FDA-approved for treating heart failure.

MINNEAPOLIS, July 29, 2021 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative and minimally invasive neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will participate in the Canaccord Genuity 41^st Annual Growth Conference on Thursday, August 12, 2021. The Company is scheduled to present at the conference at 11:00 am Eastern Time the same day via webcast.

A live audio webcast of the conference presentation will be available online at the investor relations page of the Company’s website at ir.cvrx.com. A replay of the webcast will be archived on the website for approximately 90 days.

About CVRx, Inc.
CVRx is focused on the development and commercialization of Barostim™, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body’s baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the US. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.

Investor Contact:
Mark Klausner or Mike Vallie
Westwicke, an ICR Company
ir@cvrx.com

Media Contact:
Lisa Murray
Trevi Communications, Inc.
978.750.0333 / 617.835.0396
lisa@trevicomm.com

FAQ

What is the date of CVRx's presentation at the Canaccord Genuity Growth Conference?

CVRx is set to present on August 12, 2021.

At what time will CVRx's presentation take place during the conference?

The presentation will occur at 11:00 am Eastern Time.

Where can I access the CVRx conference presentation?

The presentation will be available via live audio webcast on CVRx's investor relations page.

How long will the CVRx webcast replay be available?

The replay of the webcast will be archived for approximately 90 days.

What is the main product focus of CVRx?

CVRx specializes in developing neuromodulation solutions, particularly the Barostim device for heart failure.

Has CVRx received any regulatory designations for its Barostim device?

Yes, Barostim has received FDA Breakthrough Device designation and is approved for heart failure treatment.